Roivant Expands Brepocitinib Program into LPP, Batoclimab Fails in TED

Event summary

  • Roivant initiates Phase 2b/3 trial for brepocitinib in lichen planopilaris (LPP), a rare inflammatory scalp disorder with no FDA-approved treatments.
  • Brepocitinib becomes the fourth indication in late-stage development for the drug, following dermatomyositis, non-infectious uveitis, and cutaneous sarcoidosis.
  • Immunovant's Phase 3 studies for batoclimab in thyroid eye disease (TED) fail to meet primary endpoint, though safety results align with prior findings.
  • Roivant expects FDA Priority Review decision for brepocitinib in dermatomyositis by Q3 2026.
  • Immunovant to review future plans for batoclimab with partner HanAll Biopharma.

The big picture

Roivant's expansion of brepocitinib into LPP underscores its strategy of targeting high-unmet-need orphan diseases, while the batoclimab setback highlights the challenges in developing treatments for complex autoimmune conditions. The company's ability to navigate these dynamics will be critical as it approaches potential regulatory milestones in dermatomyositis and other indications. The biopharmaceutical sector continues to grapple with the balance between rapid innovation and the stringent requirements of clinical and regulatory success.

What we're watching

Pipeline Diversification
Whether Roivant can successfully expand brepocitinib's reach into multiple high-morbidity orphan conditions.
Regulatory Momentum
The pace at which brepocitinib advances through FDA reviews across its multiple indications.
Strategic Pivot
How Immunovant will reposition batoclimab following the TED trial setback.